CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 206 enrolled
Drug / intervention
Flutamide (Eulexin) and Lupron or Zoladex +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00116220
NCT00116220Phase 3Completed
CompareCT.gov

A Phase III Trial of External Beam of Radiotherapy +/- Total Androgen Suppression for High Risk Clinically Organ-Confined Prostate Cancer

Dana-Farber Cancer Institute·interventional·Posted Jun 28, 2005·Updated Jan 6, 2022

In Brief

A Phase 3 clinical trial evaluating Flutamide (Eulexin) and Lupron or Zoladex and External Beam Radiotherapy for Prostate Cancer. Completed, enrolled 206 participants across 1 site.

Detailed Summary

This clinical study was to determine if the use of 6 months of total androgen suppression (hormonal therapy) when added to radiation therapy for localized-high risk prostate cancer would improve overall survival.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
CollaboratorsBrigham and Women's Hospital, Saint Anne's Hospital, Beth Israel Deaconess Medical Center, Metro West Medical Center

Timeline

Phase 3CompletedFinished
199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 28, 2005
Enrollment StartSep 1, 1995
Primary CompletionApr 1, 2001
Study CompletionFeb 1, 2015
TodayJul 2, 2026
Enrollment to primary: 5.6 yearsPosted 21.0 years ago

Interventions

Flutamide (Eulexin) and Lupron or Zoladexdrug

Androgen suppression therapy

External Beam Radiotherapyradiation

Once a day, 4-5 days per week for approximately 2 months